Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A Ollila; Shaolei Lu; Rebecca Masel; Adam Zayac; Kimberly Paiva; Ralph D Rogers; Adam J Olszewski

doi:10.1001/jamaoncol.2021.4381

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

JAMA Oncol. 2021 Nov 1;7(11):1714-1716. doi: 10.1001/jamaoncol.2021.4381.

Authors

Thomas A Ollila^{1

2}, Shaolei Lu^{1

3}, Rebecca Masel¹, Adam Zayac^{1

2}, Kimberly Paiva³, Ralph D Rogers^{1

4}, Adam J Olszewski^{1

2}

Affiliations

¹ Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.
² Division of Hematology-Oncology, Rhode Island Hospital, Providence, Rhode Island.
³ Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, Rhode Island.
⁴ Division of Infectious Disease, Rhode Island Hospital, Providence, Rhode Island.

Abstract

This retrospective case series study examines immune response of adults with hematologic malignant disease who were vaccinated with 1 of 3 FDA-authorized COVID-19 vaccines between February and April of 2021.

MeSH terms

Adult
Antibody Formation*
COVID-19 Vaccines / immunology*
COVID-19* / immunology
COVID-19* / prevention & control
Hematologic Diseases* / immunology
Humans
Neoplasms* / immunology
Vaccination

Substances

COVID-19 Vaccines